Back to search
FDAFDA · Food and drugs·Recall number D-0520-2017

GlipiZIDE Extended-release tablets, 2.5 mg, 30-count carton (NDC 68084-295-21), Individual dose (NDC 68084-395-11), Rx Only, Packaged and Distributed by American Health Packaging, Columbus, Ohio 43217, NDC 68084-295-21

Published March 22, 2017 · Recall initiated: February 3, 2017

Summary

FDA records drug Class II recall D-0520-2017, published March 22, 2017 and initiated February 3, 2017. Recalling firm: Amerisource Health Services; Status: Terminated; Reported quantity: 19,393 cartons (581,790 extended release tablets); Lot: Lot #160133, 160549 Exp. 08/17 Lot #162006; Exp. 09/17 Lot #163348A, 163348B; Exp. 10/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerisource Health Services
Distributor
Nationwide
Lot
Lot #160133, 160549 Exp. 08/17 Lot #162006; Exp. 09/17 Lot #163348A, 163348B; Exp. 10/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was GlipiZIDE Extended-release tablets, 2.5 mg, 30-count carton (NDC 68084-295-21), Individual dose (NDC 68084-395-11), Rx Only, Packaged and Distributed by American Health Packaging, Columbus, Ohio 43217, NDC 68084-295-21 recalled?

Yes. FDA published recall D-0520-2017 on March 22, 2017. Reported hazard: Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.

What should I do if I have this product?

Voluntary: Firm initiated · Letter